MGMT and glioblastoma: Though numerous studies have demonstrated that the MGMT promoter methylation status may determine the efficiency of TMZ treatment for the GBM patients [15–17], this biomarker has not yet been used in routine clinical practice to guide therapy for glioblastoma [18].